Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
Oliver Sartor(Mayo Clinic), Christopher Parker(Royal Marsden NHS Foundation Trust), Peter Hoskin(University of Manchester), Nicholas D. James(Royal Marsden NHS Foundation Trust), Øyvind S. Bruland(University of Oslo), Joe M. O’Sullivan(San Antonio College), Minghua Shan(San Antonio College), C. Gillies O'Bryan-Tear(San Antonio College), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Sophie D. Fosså(Oslo University Hospital), Aleš Chodacki(San Antonio College), Isabel Syndikus(San Antonio College), Anders Widmark(Umeå University), Paweł Wiechno(San Antonio College), John Logue(San Antonio College), Daniel Heinrich(San Antonio College), Svein Inge Helle(San Antonio College), Arne Solberg(Norwegian University of Science and Technology), Dag Clement Johannessen(San Antonio College), Sten Nilsson(San Antonio College), Robert L. Coleman(Texas Oncology)
Cited by 491
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
|New England Journal of Medicine|2003|2.6k